SESSION TITLE: Pharmacotherapuetics
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
PURPOSE: Translation of inhalation-by-design drug discovery to late-stage development remains a challenge. Herein, we report a preclinical “duration-by-design” program with the goal to identify a long-acting muscarinic antagonist with structural/pharmacological features ideally suited for once-daily (QD) nebulized delivery.